High-flying Hologic splits stock
Bone densitometry firm Hologic of Waltham, MA, announced a two-for-onestock split effective March 25. Hologic's share price has risensteadily since last year, when Merck received marketing approvalfor its Fosamax osteoporosis drug, and the split will
Bone densitometry firm Hologic of Waltham, MA, announced a two-for-one
stock split effective March 25. Hologic's share price has risen
steadily since last year, when Merck received marketing approval
for its Fosamax osteoporosis drug, and the split will make the
company's stock more affordable. Hologic's stock was trading at
around $50 a share the week before the split. It had been trading
at around $14 a share last March (SCAN 12/27/95).
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Key MRI Findings Predictive of Treatment Response for Unresectable Hepatocellular Carcinoma
July 14th 2025For patients with unresectable hepatocellular carcinoma, a pre-treatment MRI finding of LI-RADS tumor in vein was associated with over an 86 percent lower likelihood of responding to transcatheter arterial chemoembolization (TACE) and targeted immunotherapy.
